Drug intelligence / Profile preview

4-aminoantipyrine derivative 1

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

4-aminoantipyrine derivative 1 is a fluorescent substituted aromatic carbonyl compound synthesized via the condensation of fluorine-substituted benzoyl chlorides with 4-aminoantipyrine. It exhibits significant fluorescence emission and has demonstrated potent in vitro cytotoxic activity against human cervical cancer cells (SiHa) with an IC50 of 0.912 μM, comparable to Pazopanib. Molecular docking studies suggest its potential anticancer activity is mediated through interactions with the HPV16-E7 target protein.

Targets

HPV16 E7 (Human papillomavirus 16 E7 protein)

Beyond the preview

Go deeper on 4-aminoantipyrine derivative 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-aminoantipyrine derivative 1.